Drug profile · INN
aflibercept
AFQLIR
aflibercept (AFQLIR) is a placenta growth factor inhibitor. Associated with Bayer Australia Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — aflibercept
- US status
- approved
- Class
- Sensory organs (S01)
- Route
- INJECTION
- Patents
- 20
- Programs
- 85
- Data quality
- 0.89
Quick answer
aflibercept (AFQLIR) is a placenta growth factor inhibitor. Associated with Bayer Australia Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Placenta growth factor inhibitor
Primary target: Placenta growth factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025146482
FINÉRÉNONE DESTINÉE À ÊTRE UTILISÉE DANS UN PROCÉDÉ DE PRÉVENTION OU DE TRAITEMENT D'UNE INSUFFISANCE CARDIAQUE CHEZ UN PATIENT RECEVANT UN INHIBITEUR DE CYP3A4 OU UN INDUCTEUR DE CYP3A4
granted -
EP 4567716
ERZEUGUNG SYNTHETISCHER DARSTELLUNGEN
granted -
EP 4567715
ERZEUGUNG SYNTHETISCHER DARSTELLUNGEN
granted -
US 12280093
Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy
granted -
US 12268730
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 12202883
Anti-VEGF protein compositions and methods for producing the same
granted -
US 12168036
Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins
granted -
US 12116622
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted -
US 12077570
Anti-VEGF protein compositions and methods for producing the same
granted -
US 12054533
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11986511
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 11975045
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 11769597
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted -
US 11753459
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11732024
VEGF antagonist formulations suitable for intravitreal administration
granted -
US 11732025
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11707506
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 11667702
Stable aqueous formulations of aflibercept
granted -
US 11649273
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11559564
Use of a VEGF antagonist to treat angiogenic eye disorders
granted
Frequently asked questions
What is aflibercept?
aflibercept (AFQLIR) is a placenta growth factor inhibitor. Associated with Bayer Australia Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for aflibercept?
AFQLIR is a marketed brand name for aflibercept. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aflibercept?
aflibercept has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.